Tuesday, September 1, 2026
News Health

News Health

A phase 3 trial compares first-line fixed-duration venetoclax-obinutuzumab to fludarabine, cyclophosphamide, and rituximab/bendamustine-rituximab in patients with CLL. Medscape Medical News Source link : https://www.medscape.com/viewarticle/venetoclax-obinutuzumab-boosts-mrd-clearance-cll-2026a1000mqf?src=rss Author : Publish date : 2026-07-06...

Read more
Page 21 of 79 1 20 21 22 79

Categories

Archives

September 2026
MTWTFSS
 123456
78910111213
14151617181920
21222324252627
282930